Based on the monitoring and inspection carried out at RSUD dr Soetomo (RSDS), the test facility for the Red and White vaccine is considered ready to undergo further research. What is the Red and White vaccine that has been approved by the Food and Drug Supervisory Agency (BPOM RI) for Phase I and II clinical trials?
The Red and White Vaccine is a vaccine developed by Indonesian researchers to meet the needs of the COVID-19 vaccine in the country. In the process, the development of the Merah Putih vaccine involved various institutions such as Airlangga University (Unair) and PT Biotis Pharmaceutical Indonesia
Head of BPOM Penny K Lukito on Monday (7/2/2022) announced that BPOM had issued an Approval for the Implementation of Clinical Trials (PPUK) for the Red and White vaccine. The Red and White vaccine that will be clinically tested is a vaccine developed by Unair with Biotis.
There is another Red and White vaccine developed by other teams such as the PRBM Eijkman-BRIN team, the Bandung Institute of Technology (ITB), the University of Indonesia (UI), Padjadjaran University (Unpad) and LIPI.
The clinical trial of the vaccine will be given to three groups, with different doses to see which one provides the best immune response. If Phase I and Phase II have been completed, Phase III can be continued provided that interim research results have been obtained.
Phase III is targeted to start in April 2022, so that it can finally proceed to obtain an emergency permit for use from BPOM.
Public expectations for the birth of a COVID-19 virus vaccine made in Indonesia are very high. The Red and White Vaccine is expected to be a long-term solution in repelling the development of the virus, as well as being a source of pride for the quality of national research.